BioNTech SE

6 in Phase 3

Quick facts

BNT162b2.B.1.351 · Immunology / Infectious Disease
BNT162b2.B.1.351 is an mRNA vaccine encoding a modified spike protein from the B.1.351 (Beta) variant of SARS-CoV-2, designed to elicit immune responses against this variant.
BNT323/DB-1303 · Oncology
BNT323/DB-1303 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to redirect immune responses against cancer cells.
BNT324 · Immunology / Infectious Disease
BNT324 is an mRNA vaccine designed to elicit an immune response against RSV (respiratory syncytial virus) by encoding viral antigens.
Investigational Influenza Vaccine · Infectious Disease
Nab-paclitaxel/Paclitaxel · Oncology
Nab-paclitaxel is an albumin-bound formulation of paclitaxel that stabilizes microtubules to prevent cell division, inducing apoptosis in cancer cells.
Pumitamig · Other

BNT111 · Infectious Diseases
BNT111 is a COVID-19 vaccine candidate.
BNT162b1 · Infectious Disease
mRNA-based vaccine
BNT162b2s01
BNT162b2SA
BNT166a · Oncology
BNT166a is an mRNA vaccine designed to encode tumor-associated antigens and stimulate anti-tumor immune responses.
BNT327 Equivalent Q3W Dose · Infectious Disease
BNT327 is a COVID-19 vaccine candidate that uses a modified mRNA molecule to instruct cells to produce a piece of the SARS-CoQV-2 virus, eliciting an immune response.
BNT327 Optimized Dose · Infectious Disease
BNT327 is a mRNA-based vaccine that encodes for the SARS-CoV-2 spike protein.
Nab-placlitaxel

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: